NH HB648

Requires health insurers, health service corporations, and HMOs to cover traditional blood glucose monitors and continuous glucose monitoring systems (CGMS) with necessary supplies for individuals diagnosed with Type 2 diabetes or gestational diabetes

Prohibits insurers from requiring insulin use, specific blood glucose testing frequency, endocrinology referrals, or prior authorization as conditions for glucose monitoring coverage; formularies must include at least 2 of each device type

Exempts glucose monitoring devices and supplies from deductibles

Requires recipients to participate in follow-up care with a licensed health care practitioner every 6 months during the first 18 months of monitoring, then annually thereafter, to maintain continued coverage

Takes effect 60 days after passage and applies to individual policies, group policies, health service corporations, and health maintenance organizations